COMP <GO>
TRAX vs MLYS // GROSS PROFIT MARGIN
First Tracks Biotherapeutics Inc. (NASDAQ) VS. Mineralys Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TRAX 3
— MLYS 2
■ METRIC PARITY
LAST: $45.23 (-1.08%) • MKT CAP: $1.90B
gross-margins
—
LAST: $21.24 (-0.65%) • MKT CAP: $1.88B
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TRAX VS. MLYS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TRAX | MLYS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -28.40% | -6.60 | MLYS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.53% | -7.58% | +0.05 | TRAX | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | MLYS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.1 | 46.0 | +20.10 | TRAX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.90B | $1.88B | $22.5M | TRAX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TRAX REV | MLYS REV | TRAX GROSS % | MLYS GROSS % | TRAX FCF | MLYS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$143.0M | -$142.4M |
| FY 2024 | $0 | $0 | — | — | -$126.2M | -$166.3M |
| FY 2023 | — | $0 | — | — | — | -$81.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TRAX // BETA —
MLYS // BETA —